Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Sven Jacobson
AddedMar 31, 2024
UpdatedMay 31, 2026
Sven Jacobson

Sven Jacobson

CEO, Woolsey Pharmaceuticals

CrunchbaseLinkedIn

Sven Jacobson's Career

Woolsey Pharmaceuticals
Woolsey Pharmaceuticals

New York City, NY, US

CEO· C-Suite · Management
Critical Diagnostics
Critical Diagnostics

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Sven Jacobson's Career

Woolsey Pharmaceuticals
Woolsey Pharmaceuticals
Series B$28.3M92019New York City, NY, US
CEO· C-Suite · Management

Leadership at Woolsey Pharmaceuticals

david geliebterdavid geliebterBoard Member

Similar to Woolsey Pharmaceuticals

Amylyx PharmaceuticalsAmylyx PharmaceuticalsCambridge, MA, USTherapeuticsest. 2014Amylyx PharmaceuticalsCambridge, MA, US · est. 2014

Amylyx Pharmaceuticals: A global biopharmaceutical firm innovating therapies for ALS and neurodegenerative diseases.

Public · $448.5M262
Chase TherapeuticsChase TherapeuticsWashington, D.C., DC, USPharmaceuticalsest. 2017Chase TherapeuticsWashington, D.C., DC, US · est. 2017

Chase Therapeutics: An early-stage pharmaceutical company innovating superior brain disease treatments.

Series B · $25.3M175
Wellesley PharmaceuticalsWellesley PharmaceuticalsNewtown, PA, USPharmaceuticalsest. 2011Wellesley PharmaceuticalsNewtown, PA, US · est. 2011

Wellesley Pharmaceuticals, based in Newtown, US, develops Paxerol, a solution for Nocturia.

Series C · $7.9M30
Osprey Pharmaceuticals USAOsprey Pharmaceuticals USASan Francisco, CA, USTherapeuticsest. 1998Osprey Pharmaceuticals USASan Francisco, CA, US · est. 1998

Osprey Pharmaceuticals USA: Innovating protein therapeutics for inflammatory and immune diseases.

Series A · $29.7M30
Critical Diagnostics
Critical Diagnostics
Public$11.1M112004San Diego, CA, US
Board Member· Board

Similar to Critical Diagnostics

FYR DiagnosticsFYR DiagnosticsMissoula, MT, USBiotech, Diagnosticsest. 2016FYR DiagnosticsMissoula, MT, US · est. 2016

FYR Diagnostics: Pioneering biomarker detection tech for human health and agriculture since 2016.

Angel · $3M16
Chosen DiagnosticsChosen DiagnosticsNew Orleans, LA, USBiomarker Testsest. 2011Chosen DiagnosticsNew Orleans, LA, US · est. 2011

Provider of advanced biomarker tests for early, accurate diagnosis of severe infant bowel disease.

Seed · $2.6M6
Cardio Diagnostics HoldingsCardio Diagnostics HoldingsChicago, IL, USMedical Diagnosticsest. 2017Cardio Diagnostics HoldingsChicago, IL, US · est. 2017

Chicago-based Cardio Diagnostics uses AI to enhance early detection and prevention of cardiovascular disease.

Public9

Sven Jacobson's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Sven Jacobson

Steve ZatzSteve ZatzBoard Member · Prognos HealthOtavio McKenzieOtavio McKenzieCo-Founder · Remedy WellJeremy GabryschJeremy GabryschCo-Founder · RemedyRonald GoldRonald GoldBoard Member · NJ BioJohn FunkhouserJohn FunkhouserCEO · PharmaneticsJonathan SacksJonathan SacksCEO · PharmAdva